The U.S. Food and Drug Administration (FDA) has issued a boxed warning for Carvykti, a CAR-T cell therapy jointly developed by Johnson & Johnson and Legend Biotech, after identifying cases of severe intestinal inflammation linked to the treatment. The condition, known as Immune Effector Cell-Associated Colitis (IEC-EC), has been associated with serious and potentially fatal complications, including bowel perforation and sepsis.
The warning follows a review of data from clinical trials as well as post-marketing safety reports. According to the FDA, IEC-EC is an immune-mediated inflammatory response affecting the gastrointestinal tract that can emerge weeks or even months after patients receive Carvykti.
Patients who developed IEC-EC reported symptoms such as prolonged diarrhea, abdominal pain, and unintended weight loss. In many cases, the severity of these symptoms required hospitalization and treatment with immunosuppressive medications.
Carvykti was first approved in February 2022 and later received expanded approval in April 2024. The broader indication allows its use in adults with relapsed or refractory multiple myeloma who have previously undergone at least one line of therapy.
Multiple myeloma is a complex blood cancer that affects plasma cells in the bone marrow. Alongside the new safety warning, the FDA also updated Carvykti’s prescribing information to reflect additional findings from late-stage clinical trials. These updates include overall survival data suggesting that patients treated with Carvykti experienced improved outcomes compared with those receiving standard therapies.
Interim results from the pivotal study showed a statistically significant survival benefit for Carvykti patients after a median follow-up of 33.6 months. Despite the newly identified risks, the FDA determined that the therapy’s clinical benefits continue to outweigh its potential harms for the approved patient population.
The agency has advised healthcare professionals to closely monitor patients for signs of IEC-EC following treatment, particularly in the weeks and months after infusion. The boxed warning is intended to ensure clinicians are fully informed of the risks and can counsel patients appropriately.
The FDA’s action reflects its broader approach to oncology oversight—allowing access to advanced therapies for serious diseases while strengthening safety communication as new risks emerge.
Patients receiving Carvykti are encouraged to promptly report any gastrointestinal symptoms to their healthcare providers and to discuss the therapy’s risks and benefits in the context of their individual medical needs.
As cancer treatments become increasingly sophisticated, regulatory updates such as this highlight the ongoing effort to balance innovation with patient safety in the management of conditions like multiple myeloma.
Team Health Accessible
Health & Wellness Editorial Team
HealthAccessible editorial team delivers trusted, accessible, and evidence-based health information for everyone.
